tbuckley/cabot-search huggingface dataset:
Parallel Nonfunctionalization of CK1δ/ε Kinase Ohnologs Following a Whole-Genome Duplication Event
Authors: Daniel Evans-Yamamoto, Alexandre K Dubé, Gourav Saha, Samuel Plante, David Bradley, Isabelle Gagnon-Arsenault, Christian R Landry
Journal: Molecular Biology and Evolution (2023)

Abstract Whole-genome duplication (WGD) followed by speciation allows us to examine the parallel evolution of ohnolog pairs. In the yeast family Saccharomycetaceae, HRR25 is a rare case of repeated ohnolog maintenance. This gene has reverted to a single copy in Saccharomyces cerevisiae where it is now essential, but has been maintained as pairs in at least 7 species post-WGD. In S. cerevisiae, HRR25 encodes the casein kinase 1δ/ε and plays a role in a variety of functions through its kinase activity and protein–protein interactions (PPIs). We hypothesized that the maintenance of duplicated HRR25 ohnologs could be a result of repeated subfunctionalization. We tested this hypothesis through a functional complementation assay in S. cerevisiae, testing all pairwise combinations of 25 orthologs (including 7 ohnolog pairs). Contrary to our expectations, we observed no cases of pair-dependent complementation, which would have supported the subfunctionalization hypothesis. Instead, most post-WGD species have one ohnolog that failed to complement, suggesting their nonfunctionalization or neofunctionalization. The ohnologs incapable of complementation have undergone more rapid protein evolution, lost most PPIs that were observed for their functional counterparts and singletons from post-WGD and non-WGD species, and have nonconserved cellular localization, consistent with their ongoing loss of function. The analysis in Naumovozyma castellii shows that the noncomplementing ohnolog is expressed at a lower level and has become nonessential. Taken together, our results indicate that HRR25 orthologs are undergoing gradual nonfunctionalization.
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease
Authors: Zobair M. Younossi, Saleh A. Alqahtani, Khalid Alswat, Yusuf Yilmaz, Caglayan Keklikkiran, Jesús Funuyet-Salas, Manuel Romero-Gómez, Jian-Gao Fan, Ming-Hua Zheng, Mohamed El-Kassas, Laurent Castera, Chun-Jen Liu, Vincent Wai-Sun Wong, Shira Zelber-Sagi, Alina M. Allen, Brian Lam, Sombat Treeprasertsuk, Saeed Hameed, Hirokazu Takahashi, Takumi Kawaguchi, Jörn M. Schattenberg, Ajay Duseja, Phil N. Newsome, Sven Francque, C. Wendy Spearman, Marlen I. Castellanos Fernández, Patrizia Burra, Stuart K. Roberts, Wah-Kheong Chan, Marco Arrese, Marcelo Silva, Mary Rinella, Ashwani K. Singal, Stuart Gordon, Michael Fuchs, Naim Alkhouri, Kenneth Cusi, Rohit Loomba, Jane Ranagan, Wayne Eskridge, Achim Kautz, Janus P. Ong, Marcelo Kugelmas, Yuichiro Eguchi, Moises Diago, Ming-Lung Yu, Lynn Gerber, Lisa Fornaresio, Fatema Nader, Linda Henry, Andrei Racila, Pegah Golabi, Maria Stepanova, Patrizia Carrieri, Jeffrey V. Lazarus
Journal: Journal of Hepatology (2023)
ELF5 drives angiogenesis suppression though stabilizing WDTC1 in renal cell carcinoma
Authors: Tushuai Li, Longjiang Xu, Zhe Wei, Shaomei Zhang, Xingyu Liu, Yanzi Yang, Yue Gu, Jie Zhang
Journal: Molecular Cancer (2023)

Renal cell carcinoma (RCC) is a common malignant tumor of the urinary system. Angiogenesis is a main contributing factor for tumorigenesis. E74-like transcription factor 5 (ELF5) has been verified to participate in the progression of different cancers and can regulate angiogenesis. This study was aimed to explore the functions of ELF5 in RCC.Bioinformatics tools were used to predict the expression of ELF5 in RCC. RT-qPCR was applied for testing ELF5 expression in RCC cells. Cell behaviors were evaluated by colony formation, CCK-8, and transwell assays. The tube formation assay was used for determining angiogenesis. Methylation-specific PCR (MSP) was utilized for measuring the methylation level of ELF5 in RCC cells. ChIP and luciferase reporter assays were applied for assessing the binding of ELF5 and ubiquitin-specific protease 3 (USP3). Co-IP and GST pull-down were utilized for detecting the interaction of WD40 and tetratricopeptide repeats 1 (WDTC1) and USP3. Ubiquitination level of WDTC1 was determined by ubiquitination assay.ELF5 was lowly expressed in RCC cells and tissues. High expression of ELF5 expression notably suppressed RCC cell proliferative, migratory, and invasive capabilities, and inhibited angiogenesis. The tumor growth in mice was inhibited by ELF5 overexpression. ELF5 was highly methylated in RCC samples, and DNA methyltransferases (DNMTs) can promote hypermethylation level of ELF5 in RCC cells. ELF5 was further proved to transcriptionally activate USP3 in RCC. Moreover, USP3 inhibited WDTC1 ubiquitination. ELF5 can promote USP3-mediated WDTC1 stabilization. Additionally, WDTC1 silencing reversed the functions of ELF5 overexpression on RCC progression.Downregulation of ELF5 due to DNA hypermethylation inhibits RCC development though the USP3/WDTC1axis in RCC.
Mitochondria-targeted SkQ1 nanoparticles for dry eye disease: Inhibiting NLRP3 inflammasome activation by preventing mitochondrial DNA oxidation
Authors: Baoshan Huang, Na Zhang, Xinying Qiu, Rui Zeng, Shuimiao Wang, Mengxia Hua, Qing Li, Kaihui Nan, Sen Lin
Journal: Journal of Controlled Release (2023)
IL-33 potentiates histaminergic itch
Authors: Anna M. Trier, Aaron M. Ver Heul, Avery Fredman, Victoria Le, Zhen Wang, Kelsey Auyeung, James Meixiong, Paola Lovato, Michael J. Holtzman, Fang Wang, Xinzhong Dong, Andrew L. Ji, Brian S. Kim
Journal: Journal of Allergy and Clinical Immunology (2023)

Itch is a common symptom that can greatly diminish quality of life. Histamine is a potent endogenous pruritogen, and while antihistamines are often the first-line treatment for itch, in conditions like chronic spontaneous urticaria (CSU), many patients remain symptomatic while receiving maximal doses. Mechanisms that drive resistance to antihistamines are poorly defined.
Addressing uncertainty about the role of structured lifestyle modification for metabolic surgery patients
Authors: Enda Murphy, Francis M Finucane
Journal: Metabolism (2023)

<h2>Abstract</h2> There is good evidence that structured lifestyle modification programmes improve health in patients with metabolic and cardiovascular disorders, but there is no specific evidence that they improve outcomes in patients undergoing metabolic or obesity surgery. Despite expert consensus guidelines stating this fact, some healthcare systems still compel patients to participate in a structured lifestyle modification programme prior to metabolic or obesity surgery. There is a well-established need for individualised multidisciplinary dietetic and physical activity care for metabolic and obesity surgery patients, and the benefits of intentional weight loss prior to surgery are well proven, but these are distinct from potentially harmful requirements for patients to undertake compulsory structured lifestyle programmes of fixed duration, frequency and intensity, which may delay surgery and reinforce obesity stigma. A critical step in rejuvenating metabolic surgery is to reframe patient participation in structured lifestyle modification programmes as an opportunity for education and empowerment, not as an indicator of motivation or suitability for metabolic surgery. Large, well-designed and adequately powered clinical trials are needed to address uncertainties in the evidence base for these programmes. Given genuine equipoise, they will need to determine whether "surgery plus lifestyle" is superior to "surgery plus placebo". Moreover, they will need to determine the cost-effectiveness of these programmes and identify some of the factors giving rise to the substantial heterogeneity in responses to structured lifestyle modification.
Towards personalized genome-scale modeling of inborn errors of metabolism for systems medicine applications
Authors: Almut Heinken, Sandra El Kouche, Rosa-Maria Guéant-Rodriguez, Jean-Louis Guéant
Journal: Metabolism (2023)

Inborn errors of metabolism (IEMs) are a group of more than 1000 inherited diseases that are individually rare but have a cumulative global prevalence of 50 per 100,000 births. Recently, it has been recognized that like common diseases, patients with rare diseases can greatly vary in the manifestation and severity of symptoms. Here, we review omics-driven approaches that enable an integrated, holistic view of metabolic phenotypes in IEM patients. We focus on applications of Constraint-based Reconstruction and Analysis (COBRA), a widely used mechanistic systems biology approach, to model the effects of inherited diseases. Moreover, we review evidence that the gut microbiome is also altered in rare diseases. Finally, we outline an approach using personalized metabolic models of IEM patients for the prediction of biomarkers and tailored therapeutic or dietary interventions. Such applications could pave the way towards personalized medicine not just for common, but also for rare diseases.
Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial
Authors: Daphne A. Haas-Kogan, Mariam S. Aboian, Jane E. Minturn, Sarah E.S. Leary, Mohamed S. Abdelbaki, Stewart Goldman, Jennifer D. Elster, Adam Kraya, Matthew R. Lueder, Divya Ramakrishnan, Marc von Reppert, Kevin X. Liu, Jo Lynne Rokita, Adam C. Resnick, David A. Solomon, Joanna J. Phillips, Michael Prados, Annette M. Molinaro, Sebastian M. Waszak, Sabine Mueller
Journal: Journal of Clinical Oncology (2023)

The PNOC001 phase II single-arm trial sought to estimate progression-free survival (PFS) associated with everolimus therapy for progressive/recurrent pediatric low-grade glioma (pLGG) on the basis of phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway activation as measured by phosphorylated-ribosomal protein S6 and to identify prognostic and predictive biomarkers.
LTBK-06. IMPACT OF VORASIDENIB TREATMENT ON MUTANT <i>IDH1</i> OR <i>IDH2</i> DIFFUSE GLIOMA TUMOR GROWTH RATE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 INDIGO STUDY
Authors: Patrick Wen, Ingo Mellinghoff, Martin van den Bent, Deborah Blumenthal, Mehdi Touat, Katherine Peters, Jennifer Clarke, Joe Mendez, Shlomit Yust-Katz, Warren Mason, Francois Ducray, Yoshie Umemura, L Burt Nabors, Matthias Holdhoff, Andreas Hottinger, Yoshiki Arakawa, Juan Sepúlveda, Wolfgang Wick, Riccardo Soffietti, James Perry, Pierre Giglio, Macarena de la Fuente, Elizabeth Maher, Dan Zhao, Shuchi Pandya, Lori Steelman, Islam Hassan, Timothy Cloughesy, Benjamin Ellingson
Journal: Neuro-Oncology (2023)

Abstract INTRODUCTION The INDIGO study (NCT04164901) showed that vorasidenib, an oral, brain-penetrant, dual inhibitor of mutant isocitrate dehydrogenase (mIDH) 1/2, significantly improved imaging-based progression-free survival and time-to-next-intervention compared with placebo in patients with grade 2 mIDH1/2 glioma previously treated with surgery only. Given the limitations of traditional bi-dimensional measurements, evaluating volumetry and tumor growth rate (TGR) is an additional method of measuring treatment effect in these diffuse growing tumors. METHODS Magnetic resonance imaging (MRI) scans were performed at baseline and every 12 weeks on-treatment; up to three pre-treatment MRI scans were requested when available. Tumor volumes were derived per blinded independent review committee using a semi-automated approach. TGR was defined as percentage change in tumor volume every 6 months. Patients with evaluable baseline and ≥ 1 MRI during the corresponding period were included in the analysis. The difference in TGR in each arm was assessed by slope of tumor growth over time using a linear mixed model. RESULTS 331 patients were randomized to vorasidenib (n=168) or placebo (n=163). Median follow-up was 14.2 months. On-treatment TGR was −2.5% (95% CI, −4.7, −0.2) with vorasidenib (n=167) and 13.9% (95% CI, 11.1, 16.8) with placebo (n=161). In patients with available imaging data, TGR pre- and post-treatment with vorasidenib (n=56) was 13.2% (95% CI, 10.3, 16.3) and −3.3% (95% CI, −5.2, −1.2), respectively, while placebo (n=67) was 18.3% (95% CI, 15.0, 21.7) and 12.2% (95% CI, 9.5, 14.9), respectively. In patients who crossed over from placebo with available imaging data (n=38), TGR pre- and post-crossover was 22.4% (95% CI, 15.7, 29.4) and 5.2% (95% CI, −3.8, 15.0), respectively. CONCLUSIONS Tumor growth was observed in patients with mIDH1/2 gliomas before receiving vorasidenib or placebo. Treatment with vorasidenib reduced the TGR and shrunk tumor volume, whereas continued growth in tumor volume was observed in patients receiving placebo.
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer
Authors: Kazumasa Komura, Kensuke Hirosuna, Satoshi Tokushige, Takuya Tsujino, Kazuki Nishimura, Mitsuaki Ishida, Takuo Hayashi, Ayako Ura, Takaya Ohno, Shogo Yamazaki, Keita Nakamori, Shoko Kinoshita, Ryoichi Maenosono, Masahiko Ajiro, Yuki Yoshikawa, Tomoaki Takai, Takeshi Tsutsumi, Kohei Taniguchi, Tomohito Tanaka, Kiyoshi Takahara, Tsuyoshi Konuma, Teruo Inamoto, Yoshinobu Hirose, Fumihito Ono, Yuichi Shiraishi, Akihide Yoshimi, Haruhito Azuma
Journal: Molecular Cancer (2023)

Abstract Background Currently, only limited knowledge is available regarding the phenotypic association between fibroblast growth factor receptor 3 (FGFR3) alterations and the tumor microenvironment (TME) in bladder cancer (BLCA). Methods A multi-omics analysis on 389 BLCA and 35 adjacent normal tissues from a cohort of OMPU-NCC Consortium Japan was retrospectively performed by integrating the whole-exome and RNA-sequence dataset and clinicopathological record. A median follow-up duration of all BLCA cohort was 31 months. Results FGFR3 alterations (aFGFR3), including recurrent mutations and fusions, accounted for 44% of non-muscle invasive bladder cancer (NMIBC) and 15% of muscle-invasive bladder cancer (MIBC). Within MIBC, the consensus subtypes LumP was significantly more prevalent in aFGFR3, whereas the Ba/Sq subtype exhibited similarity between intact FGFR3 (iFGFR3) and aFGFR3 cases. We revealed that basal markers were significantly increased in MIBC/aFGFR3 compared to MIBC/iFGFR3. Transcriptome analysis highlighted TIM3 as the most upregulated immune-related gene in iFGFR3, with differential immune cell compositions observed between iFGFR3 and aFGFR3. Using EcoTyper, TME heterogeneity was discerned even within aFGFR cases, suggesting potential variations in the response to checkpoint inhibitors (CPIs). Among 72 patients treated with CPIs, the objective response rate (ORR) was comparable between iFGFR3 and aFGFR3 (20% vs 31%; p = 0.467). Strikingly, a significantly higher ORR was noted in LumP/aFGFR3 compared to LumP/iFGFR3 (50% vs 5%; p = 0.022). This trend was validated using data from the IMvigor210 trial. Additionally, several immune-related genes, including IDO1, CCL24, IL1RL1, LGALS4, and NCAM (CD56) were upregulated in LumP/iFGFR3 compared to LumP/aFGFR3 cases. Conclusions Differential pathways influenced by aFGFR3 were observed between NMIBC and MIBC, highlighting the upregulation of both luminal and basal markers in MIBC/aFGFR3. Heterogeneous TME was identified within MIBC/aFGFR3, leading to differential outcomes for CPIs. Specifically, a favorable ORR in LumP/aFGFR3 and a poor ORR in LumP/iFGFR3 were observed. We propose TIM3 as a potential target for iFGFR3 (ORR: 20%) and several immune checkpoint genes, including IDO1 and CCL24, for LumP/iFGFR3 (ORR: 5%), indicating promising avenues for precision immunotherapy for BLCA.
In situ autophagy regulation in synergy with phototherapy for breast cancer treatment
Authors: Huijuan Zhang, Xiangyang Xuan, Yaping Wang, Zijun Qi, Kexuan Cao, Yingmei Tian, Chaoqun Wang, Junbiao Chang, Zhenzhong Zhang, Lin Hou
Journal: Acta Pharmaceutica Sinica B (2023)

Autophagy is an important factor in reducing the efficacy of tumor phototherapy (including PTT and PDT). Accurate regulation of autophagy in tumor cells is a new strategy to improve the anti-tumor efficiency of PTT/PDT. This project intended to construct a tumor-activated autophagy regulator to efficiently block PTT/PDT-induced autophagy and realize synergistic sensitization to tumor phototherapy. To achieve this goal, we first synthesized TRANSFERRIN (Tf) biomimetic mineralized nano-tellurium (Tf-Te) as photosensitizer and then used disulfide bond reconstruction technology to induce Tf-Te self-assembly. The autophagy inhibitor hydroxychloroquine (HCQ) and iron ions carried by Tf were simultaneously loaded to prepare a tumor-responsive drug reservoir Tf-Te/HCQ. After entering breast cancer cells through the "self-guidance system", Tf-Te/HCQ can generate hyperpyrexia and ROS under NIR laser irradiation, to efficiently induce PTT/PDT effect. Meanwhile, the disulfide bond broke down in response to GSH, and the nanoparticles disintegrated to release Fe2+ and HCQ at fixed points. They simultaneously induce lysosomal alkalinization and increased osmotic pressure, effectively inhibit autophagy, and synergistically enhance the therapeutic effect of phototherapy. In vivo anti-tumor results have proved that the tumor inhibition rate of Tf-Te/HCQ can be as high as 88.6% on 4T1 tumor-bearing mice. This multifunctional drug delivery system might provide a new alternative for more precise and effective tumor phototherapy.
Single-dose cefixime 800 mg plus doxycycline 100 mg twice a day for 7 days compared with single-dose ceftriaxone 1 g plus single-dose azithromycin 2 g for treatment of urogenital, rectal, and pharyngeal gonorrhoea: a randomised clinical trial
Authors: Beatrice Bížová, Přemysl Procházka, Elka Nyčová, Petr Bořil, Jan Kubele, Anna Poláková, Zuzana Zemanová, Magnus Unemo, Filip Rob
Journal: Clinical Microbiology and Infection (2023)
Vosoritide therapy in children with achondroplasia aged 3−59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial
Authors: Ravi Savarirayan, William R Wilcox, Paul Harmatz, John Phillips, Lynda E Polgreen, Louise Tofts, Keiichi Ozono, Paul Arundel, Melita Irving, Carlos A Bacino, Donald Basel, Michael B Bober, Joel Charrow, Hiroshi Mochizuki, Yumiko Kotani, Howard M Saal, Clare Army, George Jeha, Yulan Qi, Lynn Han, Elena Fisheleva, Alice Huntsman-Labed, Jonathan Day
Journal: The Lancet Child & Adolescent Health (2023)
Association between out-of-pocket expense and patient satisfaction with cutaneous surgery: A prospective, randomized study
Authors: Michael D. Yi, Umer Nadir, Farhana Ikmal Hisham, Loma Dave, Amanda Maisel-Campbell, Alexandra Weil, Emily Poon, Brian A. Cahn, Ross Pearlman, Murad Alam
Journal: Journal of the American Academy of Dermatology (2023)
Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis
Authors: Qian Zhao, Jiale Dong, Han Liu, Hui Chen, Huan Yu, Shuyin Ye, Shuangjin Yu, Yu Li, Longhui Qiu, Nazi Song, Hongjiao Xu, Qi Liu, Zhiteng Luo, Yuyi Li, Rui Wang, Guodong Chen, Xianxing Jiang
Journal: Acta Pharmaceutica Sinica B (2023)

The role of co-agonists of glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) in chronic kidney disease (CKD) remains unclear. Herein we found that GLP-1R and GCGR expression levels were lower in the kidneys of mice with CKD compared to healthy mice and were correlated with disease severity. Interestingly, GLP-1R or GCGR knockdown aggravated the progression of kidney injury in both diabetic
Advanced optical imaging for the rational design of nanomedicines
Authors: Ana Ortiz-Perez, Miao Zhang, Laurence W. Fitzpatrick, Cristina Izquierdo-Lozano, Lorenzo Albertazzi
Journal: Advanced Drug Delivery Reviews (2023)

Despite the enormous potential of nanomedicines to shape the future of medicine, their clinical translation remains suboptimal. Translational challenges are present in every step of the development pipeline, from a lack of understanding of patient heterogeneity to insufficient insights on nanoparticle properties and their impact on material-cell interactions. Here, we discuss how the adoption of advanced optical microscopy techniques, such as super-resolution optical microscopies, correlative techniques, and high-content modalities, could aid the rational design of nanocarriers, by characterizing the cell, the nanomaterial, and their interaction with unprecedented spatial and/or temporal detail. In this nanomedicine arena, we will discuss how the implementation of these techniques, with their versatility and specificity, can yield high volumes of multi-parametric data; and how machine learning can aid the rapid advances in microscopy: from image acquisition to data interpretation.
Visualizing disintegration of 3D printed tablets in humans using MRI and comparison with in vitro data
Authors: Iria Seoane-Viaño, Tania Pérez-Ramos, Jiaqi Liu, Patricija Januskaite, Elena Guerra-Baamonde, Jorge González-Ramírez, Manuel Vázquez-Caruncho, Abdul W. Basit, Alvaro Goyanes
Journal: Journal of Controlled Release (2023)

Three-dimensional (3D) printing is revolutionising the way that medicines are manufactured today, paving the way towards more personalised medicine. However, there is limited in vivo data on 3D printed dosage forms, and no studies to date have been performed investigating the intestinal behaviour of these drug products in humans, hindering the complete translation of 3D printed medications into clinical practice. Furthermore, it is unknown whether conventional in vitro release tests can accurately predict the in vivo performance of 3D printed formulations in humans. In this study, selective laser sintering (SLS) 3D printing technology has been used to produce two placebo torus-shaped tablets (printlets) using different laser scanning speeds. The printlets were administered to 6 human volunteers, and in vivo disintegration times were assessed using magnetic resonance imaging (MRI). In vitro disintegration tests were performed using a standard USP disintegration apparatus, as well as an alternative method based on the use of reduced media volume and minimal agitation. Printlets fabricated at a laser scanning speed of 90 mm/s exhibited an average in vitro disintegration time of 7.2 ± 1 min (measured using the USP apparatus) and 25.5 ± 4.1 min (measured using the alternative method). In contrast, printlets manufactured at a higher laser scanning speed of 130 mm/s had an in vitro disintegration time of 2.8 ± 0.8 min (USP apparatus) and 18.8 ± 1.9 min (alternative method). When tested in humans, printlets fabricated at a laser scanning speed of 90 mm/s showed an average disintegration time of 17.3 ± 7.2 min, while those manufactured at a laser scanning speed of 130 mm/s exhibited a shorter disintegration time of 12.7 ± 6.8 min. Although the disintegration times obtained using the alternative method more closely resembled those obtained in vivo, no clear correlation was observed between the in vitro and in vivo disintegration times, highlighting the need to develop better in vitro methodology for 3D printed drug products.
Micronanoparticled risedronate exhibits potent vaccine adjuvant effects
Authors: Meifeng Nie, Shuyu Wu, Yiyi Chen, Yangtao Wu, Ruitong Chen, Yue Liu, Mingxi Yue, Yao Jiang, Dekui Qiu, Man Yang, Zikang Wang, Jiahua Gao, Hualong Xiong, Ruoyao Qi, Jinhang He, Jinlei Zhang, Liang Zhang, Yingbin Wang, Mujin Fang, Yuqiong Que, Youliang Yao, Shaowei Li, Jun Zhang, Qinjian Zhao, Quan Yuan, Tianying Zhang, Ningshao Xia
Journal: Journal of Controlled Release (2023)
Multifunctional hydrogel for synergistic reoxygenation and chemo/photothermal therapy in metastatic breast cancer recurrence and wound infection
Authors: Jing Chen, Xinyi Zhang, Jinshen Zhang, Zhaoxia Wang, Guilan Zhu, Ming Geng, Jinmiao Zhu, Yajun Chen, Wei Wang, Youcui Xu
Journal: Journal of Controlled Release (2023)